Skip to main content
. Author manuscript; available in PMC: 2014 Jan 20.
Published in final edited form as: Br J Haematol. 2011 Apr 18;153(6):753–757. doi: 10.1111/j.1365-2141.2011.08662.x

Fig 2.

Fig 2

Lower MIR29B expression is a poor prognosis marker for AML patients. Kaplan-Meier survival curves for 56 AML patients are stratified by MIR29B expression. AML patients with lower MIR29B expression had a strong trend of adverse cytogenetics (<2·6-fold; P = 0·06) and significantly poorer OS (median OS 1·3-year vs. 2·3-year; P < 0·05) compared to AML patients with higher MIR29B expression (>2·6-fold).